• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form SC 13G/A filed by MediWound Ltd.

    7/11/24 5:43:20 PM ET
    $MDWD
    Medicinal Chemicals and Botanical Products
    Health Care
    Get the next $MDWD alert in real time by email
    SC 13G/A 1 rosalind_mdwd_13ga3_july.htm Schedule 13G

     


    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    SCHEDULE 13G/A

    (Amendment No: 03)

    Under the Securities Exchange Act of 1934

    MEDIWOUND LTD.

    (Name of Issuer)

    Common Shares

    (Title of Class of Securities)

    M68830104

    (CUSIP Number)

    June 28, 2024

    (Date of Event which Requires Filing of this Statement)

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
    ¨  Rule 13d-1(b)
    x  Rule 13d-1(c)
    ¨  Rule 13d-1(d)

    * The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

    The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     

     

     

     

    CUSIP No. M68830104

     

    13G/A

     

    Page 2 of 9 Pages

     

     

     

     

     

     

     

     

     

     

    1.

     

    NAMES OF REPORTING PERSONS
    I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)

    Rosalind Advisors, Inc.

     

     

    2.

     

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
    (see instructions)
    (a)    ¨
    (b)    ¨

     

     

    3.

     

    SEC USE ONLY
     

     

     

    4.

     

    CITIZENSHIP OR PLACE OF ORGANIZATION
     
    ONTARIO, CANADA

     

     

     

     

     

     

     

    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH

     

    5.

     

    SOLE VOTING POWER  
     
    0

     

    6.

     

    SHARED VOTING POWER
     
    513,490 shares of Common Stock

    163,265 shares of Common Stock issuable upon exercise of warrants

     

    7.

     

    SOLE DISPOSITIVE POWER
     
    0

     

    8.

     

    SHARED DISPOSITIVE POWER
     
    513,490 shares of Common Stock

    163,265 shares of Common Stock issuable upon exercise of warrants

     

     

     

     

     

    9.

     

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    513,490 shares of Common Stock

    163,265 shares of Common Stock issuable upon exercise of warrants

     

     

    10.

     

    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES
    (see instructions)    ¨

     

     

    11.

     

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

    7.16%1

     

     

    12.

     

    TYPE OF REPORTING PERSON (see instructions)

    CO

     

     

     

     

     

     

     


    1 This percentage is calculated based upon 9,283,573 shares of the Issuer’s common stock outstanding as of May 28, 2024 in accordance with 6-K filed on May 29, 2024.


     

    NYC#: 139632.2


     


    CUSIP No. M68830104

     

    13G/A

     

    Page 3 of 9 Pages

     

     

     

     

     

     

     

     

     

     

    1.

     

    NAMES OF REPORTING PERSONS
    I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)

    Steven Salamon

     

     

    2.

     

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
    (see instructions)
    (a)    ¨
    (b)    ¨

     

     

    3.

     

    SEC USE ONLY
     

     

     

    4.

     

    CITIZENSHIP OR PLACE OF ORGANIZATION
     
    ONTARIO, CANADA

     

     

     

     

     

     

     

    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH

     

    5.

     

    SOLE VOTING POWER
     
    0

     

    6.

     

    SHARED VOTING POWER
     
    513,490 shares of Common Stock

    163,265 shares of Common Stock issuable upon exercise of warrants

     

    7.

     

    SOLE DISPOSITIVE POWER
     
    0

     

    8.

     

    SHARED DISPOSITIVE POWER
     
    513,490 shares of Common Stock

    163,265 shares of Common Stock issuable upon exercise of warrants

     

     

     

     

     

    9.

     

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    513,490 shares of Common Stock

    163,265 shares of Common Stock issuable upon exercise of warrants

     

     

    10.

     

    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES
    (see instructions)    ¨

     

     

    11.

     

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

    7.16%

     

     

    12.

     

    TYPE OF REPORTING PERSON (see instructions)

    IN

     

     

     

     

     

     

     

     

    CUSIP No. M68830104

     

    13G/A

     

    Page 4 of 9 Pages

     

     

     

     

     

     

     

     

     

     

    1.

     

    NAMES OF REPORTING PERSONS
    I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)

    Gilad Aharon

     

     

    2.

     

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
    (see instructions)
    (a)    ¨
    (b)    ¨

     

     

    3.

     

    SEC USE ONLY
     

     

     

    4.

     

    CITIZENSHIP OR PLACE OF ORGANIZATION
     
    ONTARIO, CANADA

     

     

     

     

     

     

     

    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH

     

    5.

     

    SOLE VOTING POWER
     
    0

     

    6.

     

    SHARED VOTING POWER
     
    513,490 shares of Common Stock

    163,265 shares of Common Stock issuable upon exercise of warrants

     

    7.

     

    SOLE DISPOSITIVE POWER
     
    0

     

    8.

     

    SHARED DISPOSITIVE POWER
     
    513,490 shares of Common Stock

    163,265 shares of Common Stock issuable upon exercise of warrants

     

     

     

     

     

    9.

     

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    513,490 shares of Common Stock

    163,265 shares of Common Stock issuable upon exercise of warrants

     

     

    10.

     

    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES
    (see instructions)    ¨

     

     

    11.

     

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

    7.16%

     

     

    12.

     

    TYPE OF REPORTING PERSON (see instructions)

    IN

     

     

     

     

     

     

     

     

     

     

     

     

     

    CUSIP No. M68830104

     

    13G/A

     

    Page 5 of 9 Pages

     

     

     

     

     

     

     

     

     

     

    1.

     

    NAMES OF REPORTING PERSONS
    I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)

    Rosalind Master Fund L.P.

     

     

    2.

     

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
    (see instructions)
    (a)    ¨
    (b)    ¨

     

     

    3.

     

    SEC USE ONLY
     

     

     

    4.

     

    CITIZENSHIP OR PLACE OF ORGANIZATION
     
    CAYMAN ISLANDS

     

     

     

     

     

     

     

    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH

     

    5.

     

    SOLE VOTING POWER
     
    0

     

    6.

     

    SHARED VOTING POWER
     
    513,490 shares of Common Stock

    163,265 shares of Common Stock issuable upon exercise of warrants

     

    7.

     

    SOLE DISPOSITIVE POWER
     
    0

     

    8.

     

    SHARED DISPOSITIVE POWER
     
    513,490 shares of Common Stock

    163,265 shares of Common Stock issuable upon exercise of warrants

     

     

     

     

     

    9.

     

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    513,490 shares of Common Stock

    163,265 shares of Common Stock issuable upon exercise of warrants

     

     

    10.

     

    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES
    (see instructions)    ¨

     

     

    11.

     

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

    7.16%

     

     

    12.

     

    TYPE OF REPORTING PERSON (see instructions)

    PN

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

    CUSIP No. M68830104

     

    13G/A

     

    Page 6 of 9 Pages

     

     

     

     

     

    Item 1.

     

    (a)

    Name of Issuer: MEDIWOUND LTD.

     

     

     

     

    (b)

    Address of Issuer’s Principal Executive Offices
    42 Hayarkon Street, Yavne, Israel 8122745

     

     

     

    Item 2.

     

    (a)

    Name of Person Filing

    Rosalind Advisors, Inc. (“Advisor” to RMF)

    Rosalind Master Fund L.P. (“RMF”)

    Steven Salamon (“President”)

    Steven Salamon is the portfolio manager of the Advisor which advises RMF.

    Gilad Aharon is the portfolio manager and member of the Advisor which advises RMF.

     

     

     

     

     

    (b)

    Address of the Principal Office or, if none, residence
    Rosalind Advisors, Inc.

    15 Wellesley Street West

    Suite 326

    Toronto, Ontario

    M4Y 0G7 Canada

     

    Rosalind Master Fund L.P.

    P.O. Box 309

    Ugland House, Grand Cayman

    KY1-1104, Cayman Islands

     

    Steven Salamon

    15 Wellesley Street West

    Suite 326

    Toronto, Ontario

    M4Y 0G7 Canada

     

    Gilad Aharon

    15 Wellesley Street West

    Suite 326

    Toronto, Ontario

    M4Y 0G7 Canada

     

     

     

     

    (c)

    Citizenship
    Rosalind Advisors, Inc.: Ontario, Canada

    Rosalind Master Fund L.P.: Cayman Islands

    Steven Salamon: Ontario, Canada

    Gilad Aharon: Ontario, Canada

     

     

     

     

    (d)

    Title of Class of Securities
    Common Stock

     

     

     

     

    (e)

    CUSIP Number
    M68830104


     

    NYC#: 139632.2


     


     

     

     

     

     

    CUSIP No. M68830104

     

    13G/A

     

    Page 7 of 9 Pages

     

     

     

     

     

    Item 3.  If this statement is filed pursuant to §§240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:

     

    (a)

    ¨

    Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o).

     

     

     

     

     

    (b)

    ¨

    Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c).

     

     

     

     

     

    (c)

    ¨

    Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c).

     

     

     

     

     

    (d)

    ¨

    Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8).

     

     

     

     

     

    (e)

    ¨

    An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E);

     

     

     

     

     

    (f)

    ¨

    An employee benefit plan or endowment fund in accordance with §240.13d-1(b)(1)(ii)(F);

     

     

     

     

     

    (g)

    ¨

    A parent holding company or control person in accordance with §240.13d-1(b)(1)(ii)(G);

     

     

     

     

     

    (h)

    ¨

    A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);

     

     

     

     

     

    (i)

    ¨

    A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);

     

     

     

     

     

    (j)

    ¨

    Group, in accordance with §240.13d-1(b)(1)(ii)(J).

     

     

     

     

    Item 4.  Ownership.

    Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1.

     

     

     

     

     

     

    (a)

     

    Amount beneficially owned:  

     

    The information as of the date of the event which requires filing of this statement required by Items 5(a) – (c) is set forth in Rows 7 – 13 of the cover page for each Reporting Person hereto and is incorporated herein by reference for each such Reporting Person.  The percentage set forth in Row 13 of the cover page for each Reporting Person is based upon 9,283,573 shares of the Issuer’s common stock outstanding as of May 28, 2024 in accordance with 6-K filed on May 29, 2024.

    Rosalind Master Fund L.P. is the record owner of 513,490 shares of common stock and 163,265 shares of Common Stock issuable upon exercise of warrants.

    Rosalind Advisors, Inc. is the investment advisor to RMF and may be deemed to be the beneficial owner of shares held by RMF.  Steven Salamon is the portfolio manager of the Advisor and may be deemed to be the beneficial owner of shares held by RMF.  Notwithstanding the foregoing, the Advisor and Mr. Salamon disclaim beneficial ownership of the shares.  

     

     

     

     

     

     

    (b)

     

    Percent of class:  

    Rosalind Advisors, Inc. – 7.16%

    Rosalind Master Fund L.P. – 7.16%

    Steven Salamon – 7.16%

     

     

     

     

     


     

    NYC#: 139632.2


     


     

     

     

     

     

    CUSIP No. M68830104

     

    13G/A

     

    Page 8 of 9 Pages

     

     

     

     

     

     

    (c)

     

    Number of shares as to which the person has:  

     

     

     

    (i)

    Shared power to vote or to direct the vote  

    Rosalind Advisors, Inc. – 513,490 shares of Common Stock

    Rosalind Master Fund L.P. – 513,490 shares of Common Stock

    Steven Salamon – 513,490 shares of Common Stock

    Gilad Aharon - 513,490 shares of Common Stock

     

     

     

     

     

     

     

     

    (ii)

    Sole power to dispose or to direct the disposition of  – 0

     

     

     

     

     

     

     

     

    (iii)

    Shared power to dispose or to direct the disposition of  

    Rosalind Advisors, Inc. – 513,490 shares of Common Stock

    Rosalind Master Fund L.P. – 513,490 shares of Common Stock

    Steven Salamon – 513,490 shares of Common Stock

    Gilad Aharon - 513,490 shares of Common Stock

     

     

     

     

     

    Instruction. For computations regarding securities which represent a right to acquire an underlying security see §240.13d-3(d)(1).

    Item 5.  Ownership of Five Percent or Less of a Class.

    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following ¨.

    Instruction. Dissolution of a group requires a response to this item.

    Item 6.  Ownership of More than Five Percent on Behalf of Another Person.

    Item 7 – 9.  Not Applicable


     

    NYC#: 139632.2


     


     

     

     

     

     

    CUSIP No. M68830104

     

    13G/A

     

    Page 9 of 9 Pages

     

     

     

     

     

    Item 10.  Certification.

     

     

     

     

     

     

     

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

     

     

     

     

     

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

    7/4/2024

    Date

     

     

    Signature

     

    Steven Salamon/President Rosalind Advisors, Inc.

    Name/Title

     

     

    Exhibit A

    Joint Filing Agreement

     

    The undersigned hereby agree that this Statement on Schedule 13G/A with respect to the beneficial ownership of shares of Common Stock of MEDIWOUND LTD. is filed jointly, on behalf of each of them.

     

     

    Rosalind Advisors, Inc.

    By: _____________________________

    Name: Steven Salamon

    Title: President

     

    Rosalind Master Fund L.P.

    By: _____________________________

    Name: Mike McDonald

    Title: Director, Rosalind (Cayman) Ltd. (as General Partner to Rosalind Master Fund)

     

    By: _____________________________

    Name: Steven Salamon


     

    NYC#: 139632.2

    Get the next $MDWD alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $MDWD

    DatePrice TargetRatingAnalyst
    6/2/2025$34.00Outperform
    Oppenheimer
    5/2/2025$25.00Buy
    Alliance Global Partners
    2/28/2025$39.00Buy
    Craig Hallum
    7/16/2024$25.00 → $30.00Buy
    Maxim Group
    12/22/2022$11.00Buy
    Maxim Group
    7/18/2022$7.00Outperform
    Oppenheimer
    8/17/2021$10.00 → $9.00Buy
    Aegis Capital
    8/11/2021$7.00 → $6.50Buy
    HC Wainwright & Co.
    More analyst ratings

    $MDWD
    SEC Filings

    View All

    SEC Form 6-K filed by MediWound Ltd.

    6-K - MediWound Ltd. (0001593984) (Filer)

    8/19/25 7:00:19 AM ET
    $MDWD
    Medicinal Chemicals and Botanical Products
    Health Care

    SEC Form 6-K filed by MediWound Ltd.

    6-K - MediWound Ltd. (0001593984) (Filer)

    8/14/25 7:05:26 AM ET
    $MDWD
    Medicinal Chemicals and Botanical Products
    Health Care

    SEC Form 6-K filed by MediWound Ltd.

    6-K - MediWound Ltd. (0001593984) (Filer)

    5/21/25 7:07:42 AM ET
    $MDWD
    Medicinal Chemicals and Botanical Products
    Health Care

    $MDWD
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Oppenheimer resumed coverage on MediWound with a new price target

    Oppenheimer resumed coverage of MediWound with a rating of Outperform and set a new price target of $34.00

    6/2/25 8:53:24 AM ET
    $MDWD
    Medicinal Chemicals and Botanical Products
    Health Care

    Alliance Global Partners initiated coverage on MediWound with a new price target

    Alliance Global Partners initiated coverage of MediWound with a rating of Buy and set a new price target of $25.00

    5/2/25 8:15:09 AM ET
    $MDWD
    Medicinal Chemicals and Botanical Products
    Health Care

    Craig Hallum initiated coverage on MediWound with a new price target

    Craig Hallum initiated coverage of MediWound with a rating of Buy and set a new price target of $39.00

    2/28/25 7:39:12 AM ET
    $MDWD
    Medicinal Chemicals and Botanical Products
    Health Care

    $MDWD
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    MediWound Reports Second Quarter 2025 Financial Results and Provides Corporate Update

    VALUE Phase III Trial of EscharEx® in Venous Leg Ulcers Continues to Enroll Patients NexoBrid® Manufacturing Expansion on Track; Full Operational Capacity Expected by Year-End 2025 Additional Strategic Research Collaborations Established with Essity and Convatec Second Quarter 2025 Revenue of $5.7 Million, Up 43% from Prior Quarter Conference Call Today, August 14, 2025, at 8:30am Eastern Time YAVNE, Israel, Aug. 14, 2025 (GLOBE NEWSWIRE) -- MediWound Ltd. (NASDAQ:MDWD), a global leader in next-generation enzymatic therapeutics for tissue repair, today announced financial results for the second quarter ended June 30, 2025, and provided a corporate update. "We continue to execute acr

    8/14/25 7:00:00 AM ET
    $MDWD
    Medicinal Chemicals and Botanical Products
    Health Care

    MediWound Announces New EscharEx® Phase II Data Demonstrating Strong Link Between Wound Bed Preparation and Wound Closure in Venous Leg Ulcers

    MediWound Announces New EscharEx® Phase II Data Demonstrating Strong Link Between Wound Bed Preparation and Wound Closure in Venous Leg Ulcers Post hoc analysis published in Advances in Wound Care, provides clinical evidence supporting wound bed preparation as a critical step in the healing process YAVNE, Israel, August 13, 2025 (GLOBE NEWSWIRE) – MediWound Ltd. (NASDAQ:MDWD), a global leader in next-generation enzymatic therapeutics for tissue repair, today announced the publication of  "The Correlation Between Wound Bed Preparation and Wound Closure in Venous Leg Ulcers: A Post Hoc Analysis of the ChronEx Multicenter Randomized Controlled Trial", in Advances in Wound Care, a leading peer

    8/13/25 8:45:00 AM ET
    $MDWD
    Medicinal Chemicals and Botanical Products
    Health Care

    MediWound to Report Second Quarter 2025 Financial Results

    MediWound to Report Second Quarter 2025 Financial Results Conference call and webcast scheduled for Thursday, August 14 at 8:30 a.m. Eastern Time YAVNE, Israel, August 4, 2025 -- MediWound Ltd. (NASDAQ:MDWD), a global leader in next-generation enzymatic therapeutics for tissue repair, today announced that it will release its financial results for the second quarter ended June 30, 2025 on Thursday, August 14, 2025. Following the release, MediWound's management will host a conference call and live webcast at 8:30 a.m. Eastern Time to discuss these financial results and provide corporate updates. Dial-in and call details are as follows: Conference Call & Webcast Details Toll-Free:       

    8/4/25 7:30:00 AM ET
    $MDWD
    Medicinal Chemicals and Botanical Products
    Health Care

    $MDWD
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    FDA Approval for NEXOBRID issued to MEDIWOUND, LTD

    Submission status for MEDIWOUND, LTD's drug NEXOBRID (SUPPL-10) with active ingredient ANACAULASE-BCDB has changed to 'Approval' on 08/15/2024. Application Category: BLA, Application Number: 761192, Application Classification:

    8/16/24 4:36:54 AM ET
    $MDWD
    Medicinal Chemicals and Botanical Products
    Health Care

    FDA Approval for NEXOBRID issued to MEDIWOUND, LTD

    Submission status for MEDIWOUND, LTD's drug NEXOBRID (ORIG-1) with active ingredient ANACAULASE-BCDB has changed to 'Approval' on 12/28/2022. Application Category: BLA, Application Number: 761192, Application Classification:

    12/30/22 4:38:06 AM ET
    $MDWD
    Medicinal Chemicals and Botanical Products
    Health Care

    FDA Approval for NEXOBRID issued to MEDIWOUND, LTD

    Submission status for MEDIWOUND, LTD's drug NEXOBRID (SUPPL-1) with active ingredient ANACAULASE-BCDB has changed to 'Approval' on 12/28/2022. Application Category: BLA, Application Number: 761192, Application Classification:

    12/29/22 1:11:07 PM ET
    $MDWD
    Medicinal Chemicals and Botanical Products
    Health Care

    $MDWD
    Financials

    Live finance-specific insights

    View All

    MediWound Reports Second Quarter 2025 Financial Results and Provides Corporate Update

    VALUE Phase III Trial of EscharEx® in Venous Leg Ulcers Continues to Enroll Patients NexoBrid® Manufacturing Expansion on Track; Full Operational Capacity Expected by Year-End 2025 Additional Strategic Research Collaborations Established with Essity and Convatec Second Quarter 2025 Revenue of $5.7 Million, Up 43% from Prior Quarter Conference Call Today, August 14, 2025, at 8:30am Eastern Time YAVNE, Israel, Aug. 14, 2025 (GLOBE NEWSWIRE) -- MediWound Ltd. (NASDAQ:MDWD), a global leader in next-generation enzymatic therapeutics for tissue repair, today announced financial results for the second quarter ended June 30, 2025, and provided a corporate update. "We continue to execute acr

    8/14/25 7:00:00 AM ET
    $MDWD
    Medicinal Chemicals and Botanical Products
    Health Care

    MediWound to Report Second Quarter 2025 Financial Results

    MediWound to Report Second Quarter 2025 Financial Results Conference call and webcast scheduled for Thursday, August 14 at 8:30 a.m. Eastern Time YAVNE, Israel, August 4, 2025 -- MediWound Ltd. (NASDAQ:MDWD), a global leader in next-generation enzymatic therapeutics for tissue repair, today announced that it will release its financial results for the second quarter ended June 30, 2025 on Thursday, August 14, 2025. Following the release, MediWound's management will host a conference call and live webcast at 8:30 a.m. Eastern Time to discuss these financial results and provide corporate updates. Dial-in and call details are as follows: Conference Call & Webcast Details Toll-Free:       

    8/4/25 7:30:00 AM ET
    $MDWD
    Medicinal Chemicals and Botanical Products
    Health Care

    MediWound Reports First Quarter 2025 Financial Results and Provides Corporate Update

    VALUE Phase III trial of EscharEx® in venous leg ulcers advancing as planned NexoBrid® manufacturing expansion on track; full operational capacity expected by year-end 2025 First quarter revenue of $4 million; full-year 2025 revenue guidance reaffirmed at $24 million Conference call today, May 21 at 8:30am Eastern Time YAVNE, Israel, May 21, 2025 (GLOBE NEWSWIRE) -- MediWound Ltd. (NASDAQ:MDWD), a global leader in next-generation enzymatic therapeutics for tissue repair, today announced financial results for the first quarter ended March 31, 2025, and provided a corporate update. "We entered 2025 with strong execution across our clinical, commercial, and operational priorities, mainta

    5/21/25 7:00:00 AM ET
    $MDWD
    Medicinal Chemicals and Botanical Products
    Health Care

    $MDWD
    Leadership Updates

    Live Leadership Updates

    View All

    MediWound Announces Appointment of Shmulik Hess, Ph.D. as Chief Operating Officer and Chief Commercial Officer

    YAVNE, Israel, Nov. 21, 2023 (GLOBE NEWSWIRE) -- MediWound Ltd. (NASDAQ:MDWD), a fully-integrated biopharmaceutical company focused on next-generation enzymatic therapeutics for tissue repair, today announced the appointment of Shmulik Hess, Ph.D. to the positions of Chief Operating Officer and Chief Commercial Officer effective as of December 1, 2023. Dr. Hess will lead and oversee all operational and commercial activities at MediWound. "We are delighted to welcome Shmulik, a distinguished industry executive, to our team. Dr. Hess joins MediWound during a crucial phase of expansion as we diligently implement our global strategy. Given Shmulik's outstanding track record in international o

    11/21/23 7:00:00 AM ET
    $ENLV
    $MDWD
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Medicinal Chemicals and Botanical Products

    MediWound Announces a Collaboration with PolyMedics Innovations (PMI) for NexoBrid® Distribution in Europe

    YAVNE, Israel, and DENKENDORF, Germany, Nov. 08, 2023 (GLOBE NEWSWIRE) -- MediWound Ltd. (NASDAQ:MDWD), a fully-integrated biopharmaceutical company focused on next-generation enzymatic therapeutics for tissue repair, and PolyMedics Innovations (PMI), an innovative biomaterials company specializing in effective wounds treatment, today announced an agreement for the promotion of NexoBrid® in Germany, Austria, Belgium, the Netherlands and Luxemburg. Feedback from key opinion leaders and customers indicates that NexoBrid, a non-surgical solution for eschar removal in burns, is a perfect complement to PMI's existing product line, including SUPRATHEL®, NovoSorb® BTM, and SUPRA SDRM®. Along wit

    11/8/23 7:00:00 AM ET
    $MDWD
    Medicinal Chemicals and Botanical Products
    Health Care

    MediWound Announces the Appointment of Hani Luxenburg as Chief Financial Officer

    YAVNE, Israel, March 16, 2023 (GLOBE NEWSWIRE) -- MediWound Ltd. (NASDAQ:MDWD), a fully integrated biopharmaceutical company specializing in next-generation biotherapeutic solutions for tissue repair and regeneration, is pleased to announce the appointment of Ms. Hani Luxenburg as its new Chief Financial Officer, effective May 14, 2023. Ms. Luxenburg will replace Mr. Boaz Gur-Lavie, who has served as MediWound's Chief Financial Officer for the past four years. Mr. Gur-Lavie will remain with the Company through July 31, 2023 to ensure an orderly transition. With over 20 years of progressive leadership experience managing financial and accounting operations, Ms. Luxenburg joins MediWound wi

    3/16/23 7:00:00 AM ET
    $MDWD
    Medicinal Chemicals and Botanical Products
    Health Care

    $MDWD
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by MediWound Ltd.

    SC 13G/A - MediWound Ltd. (0001593984) (Subject)

    11/14/24 7:55:11 PM ET
    $MDWD
    Medicinal Chemicals and Botanical Products
    Health Care

    Amendment: SEC Form SC 13G/A filed by MediWound Ltd.

    SC 13G/A - MediWound Ltd. (0001593984) (Subject)

    10/23/24 2:57:43 PM ET
    $MDWD
    Medicinal Chemicals and Botanical Products
    Health Care

    SEC Form SC 13G filed by MediWound Ltd.

    SC 13G - MediWound Ltd. (0001593984) (Subject)

    10/1/24 8:23:53 AM ET
    $MDWD
    Medicinal Chemicals and Botanical Products
    Health Care